Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/d41586-021-03704-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 vaccine acceptance and preference for future delivery among language minority, newcomer, and racialized peoples in Canada: a national cross-sectional and longitudinal study.
Ann Med
December 2025
Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
Background: Despite high COVID-19 vaccine coverage in Canada, vaccine acceptance and preferred delivery among newcomers, racialized persons, and those who primarily speak minority languages are not well understood. This national study explores COVID-19 vaccine acceptance, access to vaccines, and delivery preferences among ethnoculturally diverse population groups.
Methods: We conducted two national cross-sectional surveys during the pandemic (Dec 2020 and Oct-Nov 2021).
Increased incidence of Graves' disease during the COVID-19 pandemic in children and adolescents in the United States.
Front Endocrinol (Lausanne)
December 2024
Division of Pediatric Endocrinology, Cohen Children's Medical Center, NorthwellHealth, New Hyde Park, NY, United States.
Introduction: Reports in adults indicate that Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) infection and vaccination trigger the expression of autoimmune disease such as Graves' disease, but the incidence of new onset Graves' disease and its temporal relationship to the peaks of COVID-19 cases in children are unclear.
Methods: This is a retrospective study of children and adolescents with new-onset Graves' disease diagnosed between September 2017 and August 2022, N=156, mean age of 12.5 ± 4 year (y), with a range of 2.
Vaccination coverage according to race or skin color in children born in 2017-2018 in Natal, Rio Grande do Norte, Brazil: a population survey.
Epidemiol Serv Saude
December 2024
Universidade de Brasília, Brasília, DF, Brazil.
Objective: To analyze vaccination coverage up to 24 months of age according to race/ skin color in the 2017-2018 live birth cohort in Natal, Rio Grande do Norte, Brazil.
Methods: Population-based survey conducted in 2020 and 2021. Vaccination coverage up to 24 months of age was estimated according to administered, valid and timely doses.
Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018.
Hum Vaccin Immunother
December 2024
Medicine, Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. Understanding the vaccine effectiveness (VE) of the seasonal influenza vaccines in immunocompromised (IC) populations remains paramount. Using 2017-2018 US Flu VE Network data, we examined the VE of the 2017-2018 seasonal influenza vaccine against symptomatic influenza in outpatient settings among IC adults.
View Article and Find Full Text PDFRespiratory syncytial virus vaccination among US adults aged ≥60 years.
Front Immunol
December 2024
Department of Infectious Diseases, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: Respiratory syncytial virus (RSV) vaccines have been recommended for US adults aged ≥60 years for nearly one year. However, the extent of vaccination coverage and the factors influencing uptake remain underexplored. This study aimed to evaluate national and state-specific RSV vaccination coverage among US adults aged ≥60 years and to identify demographic and socioeconomic factors that influence vaccination uptake.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!